What did the 2009 Science paper show?

That the circadian clock controls the NAD+ salvage pathway, while SIRT1 — which consumes NAD+ — acts back on the clock.

Why does a loop matter?

Perturbing either arm affects the other, so there is no single direction of causation — harder to reason about than a linear pathway.

NAD+

The Clock Controls NAD, and NAD Feeds Back on the Clock

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Nakahata and colleagues reported circadian control of the NAD+ salvage pathway by CLOCK and SIRT1 in Science in 2009. The clock regulates NAD+ synthesis, and SIRT1 — which consumes NAD+ — regulates the clock, forming a closed loop.

Key facts

Study: Nakahata 2009 (PMID 19286518)
Journal: Science, 1 May 2009
Clock component: CLOCK
NAD-consuming enzyme: SIRT1
Pathway controlled: NAD+ salvage
Structure: A closed feedback loop

Why a loop rather than a line

The finding is not simply that NAD+ varies with time of day. It is that the clock controls the salvage pathway producing NAD+, while SIRT1 — whose activity depends on NAD+ availability and which consumes it — acts back on the clock machinery. Each arm influences the other, which makes it self-regulating rather than merely rhythmic.

What the salvage pathway is

Cells mostly recycle NAD+ from nicotinamide released when consuming enzymes break it down, rather than building it from scratch. That recycling route is the salvage pathway, and its rate-limiting enzyme is where control is exercised — which is the point the circadian machinery acts on.

Research material referenced

NAD+ 500mg — third-party HPLC tested

View — £49.99

Why coupling metabolism to time makes sense

Feeding, activity and rest follow a daily cycle in most organisms, so metabolic demand does too. A cofactor central to energy extraction being produced in anticipation of demand rather than in response to it is an efficient arrangement, and the clock is the mechanism that permits anticipation.

What a closed loop implies

That perturbing either arm affects the other. Disrupting circadian timing would be expected to disturb NAD+ metabolism, and altering NAD+ availability would be expected to influence clock function. Loops do not have a single direction of causation, which makes them harder to reason about than linear pathways.

How this connects to other material on this site

The DSIP category covers a 2009 hypothesis linking that peptide, glucocorticoid signalling and circadian mechanisms to obesity. Circadian regulation recurs across metabolic biology, and NAD+ is one of the clearest cases where the clock and a metabolic pathway are demonstrably wired together rather than merely correlated.

What is not claimed

Anything about sleep, timing, metabolism or ageing in any person. This describes a molecular feedback loop reported in Science in 2009. Material supplied here is for laboratory research only.

Extended research context

The NAD+ deep dive

Deep dive: the compound in this catalogue that is not a peptide

NAD+ contains no amino acids and no peptide bonds. It is a dinucleotide - a nicotinamide nucleotide and an adenine nucleotide joined through a pyrophosphate bridge - which is the structural grammar of ATP and of RNA, not of a protein. It sits in a peptide catalogue because it reaches the same buyers, not because it belongs there. Saying so matters practically rather than pedantically: essentially all of the general handling guidance on this site is written for peptides and is the wrong guidance here. There is no sequence to verify, so purity by amino acid analysis is meaningless. There are no deletion sequences, because there is no stepwise coupling to produce them. Net peptide content, the figure that decides how much material a lyophilised peptide vial actually contains, has no analogue at all. Even the instruction that does carry over - dry, cold, dark - protects different chemistry, guarding glycosidic and pyrophosphate bonds rather than peptide bonds and methionine residues.

Deep dive: why the finished molecule is the least deliverable of the three

NAD+ carries two negatively charged phosphates and weighs 663.4 Da, and neither property is compatible with crossing a lipid bilayer. Extracellular NAD+ is also actively consumed: CD38 is an ectoenzyme with its active site facing outward, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by raising CD38 activity. Put those together and administered NAD+ is a molecule that cannot get in and is being degraded while it waits. Whatever follows most plausibly runs through its breakdown to smaller nicotinamide-containing species, which cells then take up and rebuild NAD+ from internally - which is to say, through exactly the precursors people otherwise take directly. This is why every substantial randomised trial in the field used nicotinamide riboside at 255.25 Da or nicotinamide mononucleotide at 334.22 Da rather than the coenzyme itself. The naming inverts the pharmacology: the finished molecule sounds like the most direct option and is the least.

Deep dive: good early evidence, and the gap that keeps getting closed rhetorically

The randomised human literature here is better than for most of this catalogue. NADPARK was a randomised phase I trial of nicotinamide riboside in Parkinson disease in Cell Metabolism. Orr and colleagues ran a randomised placebo-controlled study in older adults in GeroScience. Yoshino and colleagues published NMN and muscle insulin sensitivity in Science. These are real trials in real journals. What they measured, largely, is whether the intervention does what it is supposed to biologically - and raising a biomarker is not the same as changing an outcome. The step that gets taken rhetorically is from a decline that is real, through a mechanism that is identified, to a benefit that has not been demonstrated. Each link looks small; the chain is not. Nothing in this field approaches the scale of what settled the incretin questions, where TRIUMPH alone enrolled more than 5,800 participants with hard clinical endpoints.

Research applications

▸Cellular NAD+ metabolism and salvage pathway research
▸Sirtuin, PARP and CD38 enzyme activity studies
▸Redox biochemistry and NAD+/NADH ratio measurement
▸Cellular senescence and ageing biology research
▸Mitochondrial function and metabolic assay work
▸Comparative precursor uptake and conversion studies

Handling checklist

✓Verify against CID 5892, 663.4 Da, C21H27N7O14P2 - not by sequence
✓Do not apply peptide purity or net peptide content logic - neither exists here
✓Store lyophilised, cold, dry and protected from light
✓Prepare solutions fresh; nucleotide bonds hydrolyse readily in water
✓Be aware NAD+ and NADH are separately quantifiable oxidation states
✓Identity is confirmed by mass and chromatography against a reference standard

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Applying peptide handling and purity guidance to NAD+

Fix: It is a dinucleotide with no peptide bonds. Sequence verification, protease concerns, disulfide chemistry and net peptide content are all inapplicable.

✗ Assuming administered NAD+ enters cells intact

Fix: Two negative phosphate charges and 663 Da prevent membrane crossing, and CD38 degrades it extracellularly. Effects most plausibly run through breakdown products.

✗ Reading precursor trial results as evidence for NAD+ itself

Fix: Every substantial randomised trial used NR or NMN. NAD+ has essentially no comparable human literature.

✗ Treating a biomarker increase as a demonstrated benefit

Fix: Raising NAD+-related markers is reasonably supported. Durable clinical outcome data does not exist.

✗ Taking a precursor's food supplement status as evidence of efficacy

Fix: Supplement frameworks assess safety for consumption, not efficacy, and permit no therapeutic claims.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What did the 2009 Science paper show?: That the circadian clock controls the NAD+ salvage pathway, while SIRT1 — which consumes NAD+ — acts back on the clock.
What is the salvage pathway?: The route by which cells recycle NAD+ from nicotinamide released when consuming enzymes break it down, rather than building it from scratch.
Why does a loop matter?: Perturbing either arm affects the other, so there is no single direction of causation — harder to reason about than a linear pathway.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More NAD+ articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum